Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia
Authors
Keywords
Apolipoprotein, High-density lipoprotein, Low-density lipoprotein-cholesterol, Proprotein convertase subtilisin/kexin type 9, Triglycerides
Journal
CARDIOVASCULAR DRUGS AND THERAPY
Volume 30, Issue 3, Pages 305-313
Publisher
Springer Nature
Online
2016-05-30
DOI
10.1007/s10557-016-6666-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report
- (2015) Terry A. Jacobson et al. Journal of Clinical Lipidology
- PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
- (2015) Frederick J Raal et al. LANCET
- Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
- (2015) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Evolocumab or Ezetimibe Added to Moderate- or High-Intensity Statin Therapy on LDL-C Lowering in Patients With Hypercholesterolemia
- (2014) Jennifer G. Robinson et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Genetics and Causality of Triglyceride-Rich Lipoproteins in Atherosclerotic Cardiovascular Disease
- (2014) Robert S. Rosenson et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
- (2014) Erik Stroes et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Anti-PCSK9 Monotherapy for Hypercholesterolemia
- (2014) Michael J. Koren et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
- (2014) Dirk J. Blom et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relations of Change in Plasma Levels of LDL‐C, Non‐HDL‐C and apoB With Risk Reduction From Statin Therapy: A Meta‐Analysis of Randomized Trials
- (2014) George Thanassoulis et al. Journal of the American Heart Association
- Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients
- (2013) S. Matthijs Boekholdt et al. CIRCULATION
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults
- (2013) Neil J. Stone et al. CIRCULATION
- AMG145, a Monoclonal Antibody Against Proprotein Convertase Subtilisin Kexin Type 9, Significantly Reduces Lipoprotein(a) in Hypercholesterolemic Patients Receiving Statin Therapy
- (2013) Nihar R. Desai et al. CIRCULATION
- Efficacy and Safety of Longer-Term Administration of Evolocumab (AMG 145) in Patients With Hypercholesterolemia
- (2013) Michael J. Koren et al. CIRCULATION
- Potential of Proprotein Convertase Subtilisin/Kexin Type 9 Based Therapeutics
- (2013) Evan A. Stein et al. Current Atherosclerosis Reports
- Low-Density Lipoprotein Cholesterol–Lowering Effects of AMG 145, a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease in Patients With Heterozygous Familial Hypercholesterolemia
- (2012) Frederick Raal et al. CIRCULATION
- Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins
- (2012) S. Matthijs Boekholdt et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effect of a Monoclonal Antibody to PCSK9 on Low-Density Lipoprotein Cholesterol Levels in Statin-Intolerant Patients
- (2012) David Sullivan et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The PCSK9 decade
- (2012) Gilles Lambert et al. JOURNAL OF LIPID RESEARCH
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
- (2012) Michael J Koren et al. LANCET
- Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase 2 study
- (2012) Robert P Giugliano et al. LANCET
- Pathophysiology of hypertriglyceridemia
- (2011) H.C. Hassing et al. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS
- Triglycerides and Cardiovascular Disease
- (2011) Michael Miller et al. CIRCULATION
- Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients
- (2011) H. Soran et al. ANNALS OF CLINICAL BIOCHEMISTRY
- Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)
- (2009) V. Charlton-Menys et al. CLINICAL CHEMISTRY
- Managing diabetic dyslipidemia: Beyond statin therapy
- (2009) Hemanth Neeli et al. Current Diabetes Reports
- Lipoprotein Management in Patients With Cardiometabolic Risk
- (2008) John D. Brunzell et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started